News of a second complaint filed to Indian regulators sent the drugmaker’s shares tumbling yet again, this time to their lowest point in about six years. The new complaint was said focus on a large number of dubious transactions between a Sun distributor and a firm controlled by Sun helmsman Dilip Shangvhi’s brother-in-law.
![Zonder mens geen merk: waarom AI nooit merkvertrouwen kan automatiseren [onderzoek]](https://www.pharmamarketeer.nl/wp-content/uploads/2025/11/206-80x60.jpg)
